Literature DB >> 19683510

Internalization of MUC1 by anti-MUC1 antibody from cell membrane through the macropinocytotic pathway.

Akinori Hisatsune1, Mitsuru Kawasaki, Hideki Nakayama, Yuji Mikami, Takeshi Miyata, Yoichiro Isohama, Hiroshi Katsuki, Kwang Chul Kim.   

Abstract

MUC1 is a type I transmembrane glycoprotein aberrantly overexpressed in various cancer cells. It is thought to serve as a physical barrier from the extracellular environment and also as a receptor for various extracellular molecules. However, little is known about the fate of MUC1 during and after the interaction with these molecules. In the present study, we used anti-MUC1 antibody as an interacting molecule and investigated the cellular trafficking of MUC1. Our results showed that: (1) anti-MUC1 antibody was internalized only in MUC1 expressing cells and triggered internalization and down-regulation of MUC1; (2) the internalization of MUC1 by anti-MUC1 antibody required the cytoplasmic tail of MUC1 and was suppressed by inhibitors of Na(+)/H(+) exchanger, and caveola/raft-dependent internalization, but not by an inhibitor of clathrin-dependent internalization. We conclude that antibody-induced internalization of MUC1 involves the macropinocytotic pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19683510     DOI: 10.1016/j.bbrc.2009.08.059

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.

Authors:  Marleen van Oosten; Lucia Ma Crane; Joost Bart; Fijs W van Leeuwen; Gooitzen M van Dam
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

2.  A putative polypeptide N-acetylgalactosaminyltransferase/Williams-Beuren syndrome chromosome region 17 (WBSCR17) regulates lamellipodium formation and macropinocytosis.

Authors:  Yoshiaki Nakayama; Naosuke Nakamura; Sayoko Oki; Masaki Wakabayashi; Yasushi Ishihama; Ayumi Miyake; Nobuyuki Itoh; Akira Kurosaka
Journal:  J Biol Chem       Date:  2012-07-11       Impact factor: 5.157

3.  Membrane curvature regulates the spatial distribution of bulky glycoproteins.

Authors:  Chih-Hao Lu; Kayvon Pedram; Ching-Ting Tsai; Taylor Jones; Xiao Li; Melissa L Nakamoto; Carolyn R Bertozzi; Bianxiao Cui
Journal:  Nat Commun       Date:  2022-06-02       Impact factor: 17.694

4.  Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.

Authors:  Furong Dai; Yi Zhang; Xin Zhu; Nianchun Shan; Yuxiang Chen
Journal:  Target Oncol       Date:  2012-11-20       Impact factor: 4.493

5.  Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.

Authors:  Shu-Ta Wu; Anthony J Fowler; Corey B Garmon; Adam B Fessler; Joshua D Ogle; Kajal R Grover; Bailey C Allen; Chandra D Williams; Ru Zhou; Mahboubeh Yazdanifar; Craig A Ogle; Pinku Mukherjee
Journal:  BMC Cancer       Date:  2018-04-23       Impact factor: 4.430

6.  Effect of an alkyl spacer on the morphology and internalization of MUC1 aptamer-naphthalimide amphiphiles for targeting and imaging triple negative breast cancer cells.

Authors:  Huihui Kuang; Zachary Schneiderman; Ahmed M Shabana; Gabriella C Russo; Jun Guo; Denis Wirtz; Efrosini Kokkoli
Journal:  Bioeng Transl Med       Date:  2020-11-10

7.  Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.

Authors:  Jason J Lohmueller; Shuji Sato; Lana Popova; Isabel M Chu; Meghan A Tucker; Roberto Barberena; Gregory M Innocenti; Mare Cudic; James D Ham; Wan Cheung Cheung; Roberto D Polakiewicz; Olivera J Finn
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

8.  Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells.

Authors:  Katarzyna Supruniuk; Robert Czarnomysy; Anna Muszyńska; Iwona Radziejewska
Journal:  Pharmaceutics       Date:  2021-06-26       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.